Company Overview

Endonovo Therapeutics, Inc. (OTC: ENDV) is a U.S.-based biotechnology and medical technology company focused on the development of non-invasive therapeutic devices and regenerative medicine technologies. Public disclosures indicate that the company has historically operated in the bioelectronics, electroceutical therapy, and immunotherapy sectors, with an emphasis on treatments designed to reduce inflammation, accelerate healing, and support recovery from chronic medical conditions. The company’s business activities have centered on commercializing medical devices that use electromagnetic or pulsed-field technologies for therapeutic applications.

The company’s primary revenue and development focus has historically involved its electroceutical platform technologies, including the SofPulse device platform, which has been marketed for post-operative pain management and tissue healing applications. Endonovo has also publicly discussed initiatives involving stem-cell-related therapeutics and inflammatory disease research. The company has targeted healthcare providers, rehabilitation markets, and patients requiring post-surgical recovery support. Based on available public filings and disclosures, Endonovo’s strategic positioning has relied on pursuing lower-risk medical device commercialization pathways relative to traditional pharmaceutical development. Some historical product development timelines and commercialization objectives have changed over time, and certain operational details remain limited in recent public disclosures.

Business Operations

Endonovo Therapeutics has historically operated through medical device and regenerative medicine initiatives, with a concentration on electroceutical technologies. Its principal operating activities have included development, licensing, and commercialization efforts tied to therapeutic devices designed to modulate inflammation and improve healing outcomes. The company’s publicly referenced technology platforms have included the SofPulse system and related pulsed electromagnetic field therapy applications. Public records also indicate prior efforts involving biologics and stem-cell-based therapeutic concepts, though the degree of active commercialization in those areas has varied across reporting periods.

The company’s operations have primarily been based in the United States, with limited evidence of large-scale international operating infrastructure. Endonovo has previously disclosed strategic collaborations and licensing relationships intended to expand distribution and clinical utilization of its therapeutic technologies. Publicly available information suggests that the company has relied heavily on external partnerships, intellectual property licensing arrangements, and capital markets financing to support operations. Data regarding current large-scale subsidiaries, material joint ventures, or sustained international revenue streams is inconclusive based on available public sources.

Strategic Position & Investments

Endonovo Therapeutics’ strategic direction has historically focused on expanding adoption of non-invasive therapeutic technologies in post-operative recovery, wound healing, pain management, and inflammatory conditions. Company disclosures and investor communications have emphasized efforts to position electroceutical therapies as alternatives or complements to pharmaceutical treatment approaches, particularly in areas where reduced opioid usage and accelerated recovery are considered important healthcare priorities.

The company has pursued growth through intellectual property development, commercialization partnerships, and selective acquisitions or licensing arrangements tied to regenerative medicine and medical device technologies. Public disclosures have referenced interests in emerging healthcare sectors involving bioelectronic medicine and immunomodulation. However, the scale and commercial maturity of several initiatives have remained limited relative to larger publicly traded medical technology companies. Information regarding recent major acquisitions, portfolio holdings, or material long-term investments is limited in currently available public reporting.

Geographic Footprint

Endonovo Therapeutics is headquartered in the United States, and its operational activities have primarily been concentrated in the domestic healthcare market. Public filings and investor materials indicate that the company’s commercialization strategy has historically focused on U.S. hospitals, outpatient recovery markets, rehabilitation providers, and healthcare practitioners utilizing non-invasive therapeutic technologies.

While the company has referenced broader market opportunities beyond the United States, publicly available information does not indicate a substantial multinational operational footprint comparable to larger global medical device manufacturers. Evidence of significant infrastructure, manufacturing operations, or revenue concentration across Europe, Asia-Pacific, or Latin America remains limited based on available public disclosures.

Leadership & Governance

Endonovo Therapeutics has undergone multiple leadership and strategic transitions during its operating history, reflecting the evolving nature of its development-stage business model. Governance and operational strategy have generally focused on advancing commercialization opportunities for electroceutical technologies while maintaining access to external financing and strategic partnerships. Public disclosures suggest that management priorities have included clinical validation, regulatory positioning, and expansion of therapeutic use cases for the company’s technology platforms.

Key executives and leadership figures publicly associated with the company in recent and historical filings include:

• Alan Collier – Chief Executive Officer
• Augustine Y. Lien – Founder and former executive leadership figure
• Paul Levesque – Former executive leadership and commercialization executive
• Mark Green – Former executive and operational leadership role

Leadership composition and executive roles have changed periodically over time. Certain governance and management details may vary across reporting periods, and some information is inconclusive based on available public sources.